News and Trends 11 Jan 2018 Here’s Another Reason to Eat Plenty of Fruit and Vegetables Researchers have discovered that bacteria break down fruit and vegetables to produce chemicals that control our genes and could help to prevent cancer and fight infections. British scientists from the Babraham Institute in Cambridge, UK, with colleagues from Brazil and Italy, have discovered a mechanism by which helpful bacteria in the gut can control the […] January 11, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Inside Labiotech 11 Jan 2018 A Day In The Life of a Labiotech-er I read the news today oh boy… You read the articles, but what exactly goes on behind the scenes? Here’s a sneak preview of a day in the life of your favorite Labiotech team. 8:00 am: Evelyn, our Editor-in-Chief arrives. Why so early? Because she’s crazy. Also because the early bird gets the worm. 9-9:30 […] January 11, 2018 - 4 minutesmins - By Katherine Douglas Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jan 2018 New Venture Fund Closes $102M to Boost Biotech and Medical Device Development Truffle Capital has raised $102M (€85M), which will support biotechs, with a focus on medical device companies that have the potential to become market leaders. Truffle Capital, founded in 2001 and based in Paris, is a venture capital firm that focuses on supporting start-ups in life sciences and IT. The company manages assets worth over $1.1B […] January 10, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jan 2018 French Biotech Starts Trials to Restore Sight in All Types of Retinitis Pigmentosa GenSight will start a clinical trial in the UK testing a combination of gene therapy and a wearable device to restore sight in patients with retinitis pigmentosa. The UK Medicines and Healthcare Regulatory Agency (MHRA) has accepted GenSight’s application to run a first clinical trial in the UK testing a new type of therapy with the […] January 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jan 2018 These Dissolving Lenses Could Wash Away Glaucoma Patients’ Problems Students at the Kaunas University of Technology, Lithuania, are developing dissolving contact lenses, which could help individuals suffering from glaucoma. A team of students from Kaunas University of Technology (KTU) won second place at the Silicon Valley Innovation Challenge in the Best Global Innovation category for their NanoLens technology. Their idea is to produce contact lenses that contain […] January 10, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Infographics 10 Jan 2018 Infographic: All You Need to Know About Checkpoint Inhibitors Everything you need to know about what checkpoint inhibitors are and why they have caused a wave of hype for cancer immunotherapies. Since the approval of the first PD-1 checkpoint inhibitor, Keytruda, in 2014, there has been an explosion of the numbers of trials testing these drugs, both alone and in combination. The latest figure, […] January 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2018 Biocartis and Amgen Shake Hands on Another Cancer Diagnostics Deal Biocartis will use its expertise in molecular diagnostics to produce a companion diagnostic test for Amgen’s upcoming cancer drug. Biocartis has signed its second agreement with US pharma giant, Amgen, to develop a companion diagnostic to test the suitability of a drug for a specific patient. Both deals will make use of Biocartis’ Idylla platform, a fully automated […] January 9, 2018 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2018 Scancell and BioNTech Will Combine Their Expertise to Fight Cancer Scancell has brought in BioNTech to develop T-cell receptors against specific target proteins in cancer cells, opening the door to new cancer treatments that target them. Scancell works on immunotherapies for the treatment of cancer and it has announced that it will come together with Europe’s largest private biopharma, BioNTech, to develop T-cell receptor (TCR)-based therapies. […] January 9, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 9 Jan 2018 Ablynx’ Stock Jumps by 60% After Rejecting Acquisition from Novo Nordisk Ablynx has rejected a generous acquisition offer from Novo Nordisk. As a result, its stock has soared and is now worth more than what Novo offered in the first place. Early this morning, Novo Nordisk has made public an offer to acquire Ablynx, a Belgian biotech that has recently joined the European billion-euro biotech club. Novo […] January 9, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2018 Adaptimmune Gets the Green Light for its New T-cell Cancer Therapy Following successful pilot studies, Adaptimmune will increase the dose of its T-cell therapy 10-fold to see if it remains safe, while also assessing its cancer-fighting capacity. Adaptimmune is a leader in the development of T-cell therapies for the treatment of cancer. It has been testing another one of its SPEAR T-cells in two pilot studies to determine […] January 9, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 Bang and the Wart is Gone! Norwegian Peptide Destroys HPV-Infected Cells Cytovation has raised over €3M to finish off pre-clinical testing of its treatment for warts, and to take it into the clinic. Norwegian biotech Cytovation is developing technology for the treatment of dermatological problems, including cutaneous warts caused by human papillomavirus. It lead candidate, CyPep-H1, uses a new mechanism of action to specifically target and destroy […] January 8, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 Galapagos Teams up with Dutch Biotech to Edit Fibrosis out of our RNA Galapagos and ProQR will work together to target fibrosis using a technology to treat genetic diseases without permanent changes to the DNA. A new research collaboration between two biotech companies in Leiden, the Netherlands, will aim to discover a new class of drugs to treat fibrosis — a process of excessive scarring that leads to […] January 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email